Fig 1.
Histopathological samples of two patients showing comparable tissue morphology in H&E staining (A,C) but a KRT81+ subtype (B) in one patient and KRT81- subtype (D) in the other patient.
Fig 2.
Patients with a KRT81+ subtype experienced significantly diminished overall survival.
Table 1.
Multivariate Cox proportional hazards analysis results of clinical parameters.
Table 2.
Distribution of clinical parameters between the cohorts with KRT81+ and KRT81- tumor subtypes alongside crosstabulation results.
Fig 3.
ROC curves (colored) and average ROC-curve (black dotted) over 10 random stratified shuffle-splits of the dataset.
Table 3.
Radiomic features alongside their importance as ranked by the algorithm.
Fig 4.
Exemplary Kaplan-Meier disease-free survival curve drawn from the 10 cross-validation folds representing the median hazard ratio.
Patients with a high risk radiomic phenotype experienced significantly diminished survival (7.90 vs. 24.20 months median DFS, log-rank-test p = 0.004, HR = 3.17, N = 17).
Fig 5.
Exemplary Kaplan-Meier overall survival curve drawn from the 10 cross-validation folds representing the median hazard ratio.
Patients with a high risk radiomic phenotype experienced significantly diminished survival (10.97 vs. 25.70 months median OS, log-rank-test p = 0.006, HR = 3.03, N = 17).
Fig 6.
Exemplary Kaplan-Meier plot of patients with a predicted KRT81+/ high risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio.
Patients who received gemcitabine experienced improved survival, although no statistical significance is observed in this case (median survival 4.70 vs 9.30 months, p = 0.23, HR = 1.03, N = 7).
Fig 7.
Exemplary Kaplan-Meier plot of patients with a predicted KRT81-/ low risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio.
Patients who received FOLFIRINOX experienced significantly improved survival, (median survival 17.83 vs 30.10 months, p = 0.01, HR = 2.57, N = 10).
Fig 8.
Patients with KRT81+ subtype experience longer overall survival under palliative gemcitabine chemotherapy.
Fig 9.
Patients with KRT81- subtype experience improved survival under palliative FOLFIRINOX chemotherapy.